Описание

Study design for the oral probiotic (Lactiplantibacillus plantarum GTB1) intervention trial evaluating skin health outcomes is presented, detailing the randomization and supplementation protocol.

Figure 1

Flowchart

Source Paper

Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1TM) on Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study.

Nutrients (2022)

PMID: 35631156

DOI: 10.3390/nu14102015

Cite This Figure

![Figure 1: Study design for the oral probiotic (Lactiplantibacillus plantarum GTB1) intervention trial evaluating skin health outcomes is presented, detailing the randomization and supplementation protocol.]()

> Source: Kyoungmi Jung et al. "Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1TM) ." *Nutrients*, 2022. PMID: [35631156](https://pubmed.ncbi.nlm.nih.gov/35631156/)

<figure>
  <img src="" alt="Study design for the oral probiotic (Lactiplantibacillus plantarum GTB1) intervention trial evaluating skin health outcomes is presented, detailing the randomization and supplementation protocol." />
  <figcaption>Figure 1. Study design for the oral probiotic (Lactiplantibacillus plantarum GTB1) intervention trial evaluating skin health outcomes is presented, detailing the randomization and supplementation protocol.<br>  Source: Kyoungmi Jung et al. "Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1TM) ." <em>Nutrients</em>, 2022. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35631156/">35631156</a></figcaption>
</figure>

Связанные доказательства

Lactobacillus plantarum для Irritable Bowel Syndrome (IBS)

Оценка B · 5 исследований